Global Endogenous Peptide Substances Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Endogenous Peptide Substances market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
The Global Info Research report includes an overview of the development of the Endogenous Peptide Substances industry chain, the market status of Research (Neuropeptides, Hormones), Medicine (Neuropeptides, Hormones), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Endogenous Peptide Substances.
Regionally, the report analyzes the Endogenous Peptide Substances markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Endogenous Peptide Substances market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Endogenous Peptide Substances market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Endogenous Peptide Substances industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Neuropeptides, Hormones).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Endogenous Peptide Substances market.
Regional Analysis: The report involves examining the Endogenous Peptide Substances market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Endogenous Peptide Substances market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Endogenous Peptide Substances:
Company Analysis: Report covers individual Endogenous Peptide Substances players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Endogenous Peptide Substances This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Research, Medicine).
Technology Analysis: Report covers specific technologies relevant to Endogenous Peptide Substances. It assesses the current state, advancements, and potential future developments in Endogenous Peptide Substances areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Endogenous Peptide Substances market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Endogenous Peptide Substances market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Endogenous Peptide Substances product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Endogenous Peptide Substances, with revenue, gross margin and global market share of Endogenous Peptide Substances from 2018 to 2023.
Chapter 3, the Endogenous Peptide Substances competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Endogenous Peptide Substances market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Endogenous Peptide Substances.
Chapter 13, to describe Endogenous Peptide Substances research findings and conclusion.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
The Global Info Research report includes an overview of the development of the Endogenous Peptide Substances industry chain, the market status of Research (Neuropeptides, Hormones), Medicine (Neuropeptides, Hormones), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Endogenous Peptide Substances.
Regionally, the report analyzes the Endogenous Peptide Substances markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Endogenous Peptide Substances market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Endogenous Peptide Substances market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Endogenous Peptide Substances industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Neuropeptides, Hormones).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Endogenous Peptide Substances market.
Regional Analysis: The report involves examining the Endogenous Peptide Substances market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Endogenous Peptide Substances market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Endogenous Peptide Substances:
Company Analysis: Report covers individual Endogenous Peptide Substances players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Endogenous Peptide Substances This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Research, Medicine).
Technology Analysis: Report covers specific technologies relevant to Endogenous Peptide Substances. It assesses the current state, advancements, and potential future developments in Endogenous Peptide Substances areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Endogenous Peptide Substances market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Endogenous Peptide Substances market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Neuropeptides
- Hormones
- Cytokines
- Peptide Hormones
- Bioactive Peptides
- Research
- Medicine
- Others
- Assertio Therapeutics Inc.
- Cipher Pharmaceuticals Inc.
- Endo International Plc
- Biosynth Carbosynth
- Lannett Co. Inc.
- Pfizer
- Johnson & Johnson
- Peptide Institute
- Abbexa
- Phoenix Pharmaceuticals
- Creative Peptides
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Endogenous Peptide Substances product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Endogenous Peptide Substances, with revenue, gross margin and global market share of Endogenous Peptide Substances from 2018 to 2023.
Chapter 3, the Endogenous Peptide Substances competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Endogenous Peptide Substances market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Endogenous Peptide Substances.
Chapter 13, to describe Endogenous Peptide Substances research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Endogenous Peptide Substances
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Endogenous Peptide Substances by Type
1.3.1 Overview: Global Endogenous Peptide Substances Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Endogenous Peptide Substances Consumption Value Market Share by Type in 2022
1.3.3 Neuropeptides
1.3.4 Hormones
1.3.5 Cytokines
1.3.6 Peptide Hormones
1.3.7 Bioactive Peptides
1.4 Global Endogenous Peptide Substances Market by Application
1.4.1 Overview: Global Endogenous Peptide Substances Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Research
1.4.3 Medicine
1.4.4 Others
1.5 Global Endogenous Peptide Substances Market Size & Forecast
1.6 Global Endogenous Peptide Substances Market Size and Forecast by Region
1.6.1 Global Endogenous Peptide Substances Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Endogenous Peptide Substances Market Size by Region, (2018-2029)
1.6.3 North America Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.4 Europe Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.6 South America Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Endogenous Peptide Substances Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Assertio Therapeutics Inc.
2.1.1 Assertio Therapeutics Inc. Details
2.1.2 Assertio Therapeutics Inc. Major Business
2.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Product and Solutions
2.1.4 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Assertio Therapeutics Inc. Recent Developments and Future Plans
2.2 Cipher Pharmaceuticals Inc.
2.2.1 Cipher Pharmaceuticals Inc. Details
2.2.2 Cipher Pharmaceuticals Inc. Major Business
2.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product and Solutions
2.2.4 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Cipher Pharmaceuticals Inc. Recent Developments and Future Plans
2.3 Endo International Plc
2.3.1 Endo International Plc Details
2.3.2 Endo International Plc Major Business
2.3.3 Endo International Plc Endogenous Peptide Substances Product and Solutions
2.3.4 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Endo International Plc Recent Developments and Future Plans
2.4 Biosynth Carbosynth
2.4.1 Biosynth Carbosynth Details
2.4.2 Biosynth Carbosynth Major Business
2.4.3 Biosynth Carbosynth Endogenous Peptide Substances Product and Solutions
2.4.4 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biosynth Carbosynth Recent Developments and Future Plans
2.5 Lannett Co. Inc.
2.5.1 Lannett Co. Inc. Details
2.5.2 Lannett Co. Inc. Major Business
2.5.3 Lannett Co. Inc. Endogenous Peptide Substances Product and Solutions
2.5.4 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Lannett Co. Inc. Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Endogenous Peptide Substances Product and Solutions
2.6.4 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Endogenous Peptide Substances Product and Solutions
2.7.4 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Johnson & Johnson Recent Developments and Future Plans
2.8 Peptide Institute
2.8.1 Peptide Institute Details
2.8.2 Peptide Institute Major Business
2.8.3 Peptide Institute Endogenous Peptide Substances Product and Solutions
2.8.4 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Peptide Institute Recent Developments and Future Plans
2.9 Abbexa
2.9.1 Abbexa Details
2.9.2 Abbexa Major Business
2.9.3 Abbexa Endogenous Peptide Substances Product and Solutions
2.9.4 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Abbexa Recent Developments and Future Plans
2.10 Phoenix Pharmaceuticals
2.10.1 Phoenix Pharmaceuticals Details
2.10.2 Phoenix Pharmaceuticals Major Business
2.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Product and Solutions
2.10.4 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Phoenix Pharmaceuticals Recent Developments and Future Plans
2.11 Creative Peptides
2.11.1 Creative Peptides Details
2.11.2 Creative Peptides Major Business
2.11.3 Creative Peptides Endogenous Peptide Substances Product and Solutions
2.11.4 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Creative Peptides Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Endogenous Peptide Substances Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Endogenous Peptide Substances by Company Revenue
3.2.2 Top 3 Endogenous Peptide Substances Players Market Share in 2022
3.2.3 Top 6 Endogenous Peptide Substances Players Market Share in 2022
3.3 Endogenous Peptide Substances Market: Overall Company Footprint Analysis
3.3.1 Endogenous Peptide Substances Market: Region Footprint
3.3.2 Endogenous Peptide Substances Market: Company Product Type Footprint
3.3.3 Endogenous Peptide Substances Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Endogenous Peptide Substances Consumption Value and Market Share by Type (2018-2023)
4.2 Global Endogenous Peptide Substances Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2023)
5.2 Global Endogenous Peptide Substances Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Endogenous Peptide Substances Consumption Value by Type (2018-2029)
6.2 North America Endogenous Peptide Substances Consumption Value by Application (2018-2029)
6.3 North America Endogenous Peptide Substances Market Size by Country
6.3.1 North America Endogenous Peptide Substances Consumption Value by Country (2018-2029)
6.3.2 United States Endogenous Peptide Substances Market Size and Forecast (2018-2029)
6.3.3 Canada Endogenous Peptide Substances Market Size and Forecast (2018-2029)
6.3.4 Mexico Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Endogenous Peptide Substances Consumption Value by Type (2018-2029)
7.2 Europe Endogenous Peptide Substances Consumption Value by Application (2018-2029)
7.3 Europe Endogenous Peptide Substances Market Size by Country
7.3.1 Europe Endogenous Peptide Substances Consumption Value by Country (2018-2029)
7.3.2 Germany Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.3 France Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.5 Russia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.6 Italy Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Endogenous Peptide Substances Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Endogenous Peptide Substances Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Endogenous Peptide Substances Market Size by Region
8.3.1 Asia-Pacific Endogenous Peptide Substances Consumption Value by Region (2018-2029)
8.3.2 China Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.3 Japan Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.4 South Korea Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.5 India Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.7 Australia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Endogenous Peptide Substances Consumption Value by Type (2018-2029)
9.2 South America Endogenous Peptide Substances Consumption Value by Application (2018-2029)
9.3 South America Endogenous Peptide Substances Market Size by Country
9.3.1 South America Endogenous Peptide Substances Consumption Value by Country (2018-2029)
9.3.2 Brazil Endogenous Peptide Substances Market Size and Forecast (2018-2029)
9.3.3 Argentina Endogenous Peptide Substances Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Endogenous Peptide Substances Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Endogenous Peptide Substances Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Endogenous Peptide Substances Market Size by Country
10.3.1 Middle East & Africa Endogenous Peptide Substances Consumption Value by Country (2018-2029)
10.3.2 Turkey Endogenous Peptide Substances Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
10.3.4 UAE Endogenous Peptide Substances Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Endogenous Peptide Substances Market Drivers
11.2 Endogenous Peptide Substances Market Restraints
11.3 Endogenous Peptide Substances Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Endogenous Peptide Substances Industry Chain
12.2 Endogenous Peptide Substances Upstream Analysis
12.3 Endogenous Peptide Substances Midstream Analysis
12.4 Endogenous Peptide Substances Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Endogenous Peptide Substances
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Endogenous Peptide Substances by Type
1.3.1 Overview: Global Endogenous Peptide Substances Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Endogenous Peptide Substances Consumption Value Market Share by Type in 2022
1.3.3 Neuropeptides
1.3.4 Hormones
1.3.5 Cytokines
1.3.6 Peptide Hormones
1.3.7 Bioactive Peptides
1.4 Global Endogenous Peptide Substances Market by Application
1.4.1 Overview: Global Endogenous Peptide Substances Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Research
1.4.3 Medicine
1.4.4 Others
1.5 Global Endogenous Peptide Substances Market Size & Forecast
1.6 Global Endogenous Peptide Substances Market Size and Forecast by Region
1.6.1 Global Endogenous Peptide Substances Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Endogenous Peptide Substances Market Size by Region, (2018-2029)
1.6.3 North America Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.4 Europe Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.6 South America Endogenous Peptide Substances Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Endogenous Peptide Substances Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Assertio Therapeutics Inc.
2.1.1 Assertio Therapeutics Inc. Details
2.1.2 Assertio Therapeutics Inc. Major Business
2.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Product and Solutions
2.1.4 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Assertio Therapeutics Inc. Recent Developments and Future Plans
2.2 Cipher Pharmaceuticals Inc.
2.2.1 Cipher Pharmaceuticals Inc. Details
2.2.2 Cipher Pharmaceuticals Inc. Major Business
2.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product and Solutions
2.2.4 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Cipher Pharmaceuticals Inc. Recent Developments and Future Plans
2.3 Endo International Plc
2.3.1 Endo International Plc Details
2.3.2 Endo International Plc Major Business
2.3.3 Endo International Plc Endogenous Peptide Substances Product and Solutions
2.3.4 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Endo International Plc Recent Developments and Future Plans
2.4 Biosynth Carbosynth
2.4.1 Biosynth Carbosynth Details
2.4.2 Biosynth Carbosynth Major Business
2.4.3 Biosynth Carbosynth Endogenous Peptide Substances Product and Solutions
2.4.4 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biosynth Carbosynth Recent Developments and Future Plans
2.5 Lannett Co. Inc.
2.5.1 Lannett Co. Inc. Details
2.5.2 Lannett Co. Inc. Major Business
2.5.3 Lannett Co. Inc. Endogenous Peptide Substances Product and Solutions
2.5.4 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Lannett Co. Inc. Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Endogenous Peptide Substances Product and Solutions
2.6.4 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Endogenous Peptide Substances Product and Solutions
2.7.4 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Johnson & Johnson Recent Developments and Future Plans
2.8 Peptide Institute
2.8.1 Peptide Institute Details
2.8.2 Peptide Institute Major Business
2.8.3 Peptide Institute Endogenous Peptide Substances Product and Solutions
2.8.4 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Peptide Institute Recent Developments and Future Plans
2.9 Abbexa
2.9.1 Abbexa Details
2.9.2 Abbexa Major Business
2.9.3 Abbexa Endogenous Peptide Substances Product and Solutions
2.9.4 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Abbexa Recent Developments and Future Plans
2.10 Phoenix Pharmaceuticals
2.10.1 Phoenix Pharmaceuticals Details
2.10.2 Phoenix Pharmaceuticals Major Business
2.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Product and Solutions
2.10.4 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Phoenix Pharmaceuticals Recent Developments and Future Plans
2.11 Creative Peptides
2.11.1 Creative Peptides Details
2.11.2 Creative Peptides Major Business
2.11.3 Creative Peptides Endogenous Peptide Substances Product and Solutions
2.11.4 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Creative Peptides Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Endogenous Peptide Substances Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Endogenous Peptide Substances by Company Revenue
3.2.2 Top 3 Endogenous Peptide Substances Players Market Share in 2022
3.2.3 Top 6 Endogenous Peptide Substances Players Market Share in 2022
3.3 Endogenous Peptide Substances Market: Overall Company Footprint Analysis
3.3.1 Endogenous Peptide Substances Market: Region Footprint
3.3.2 Endogenous Peptide Substances Market: Company Product Type Footprint
3.3.3 Endogenous Peptide Substances Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Endogenous Peptide Substances Consumption Value and Market Share by Type (2018-2023)
4.2 Global Endogenous Peptide Substances Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2023)
5.2 Global Endogenous Peptide Substances Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Endogenous Peptide Substances Consumption Value by Type (2018-2029)
6.2 North America Endogenous Peptide Substances Consumption Value by Application (2018-2029)
6.3 North America Endogenous Peptide Substances Market Size by Country
6.3.1 North America Endogenous Peptide Substances Consumption Value by Country (2018-2029)
6.3.2 United States Endogenous Peptide Substances Market Size and Forecast (2018-2029)
6.3.3 Canada Endogenous Peptide Substances Market Size and Forecast (2018-2029)
6.3.4 Mexico Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Endogenous Peptide Substances Consumption Value by Type (2018-2029)
7.2 Europe Endogenous Peptide Substances Consumption Value by Application (2018-2029)
7.3 Europe Endogenous Peptide Substances Market Size by Country
7.3.1 Europe Endogenous Peptide Substances Consumption Value by Country (2018-2029)
7.3.2 Germany Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.3 France Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.5 Russia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
7.3.6 Italy Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Endogenous Peptide Substances Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Endogenous Peptide Substances Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Endogenous Peptide Substances Market Size by Region
8.3.1 Asia-Pacific Endogenous Peptide Substances Consumption Value by Region (2018-2029)
8.3.2 China Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.3 Japan Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.4 South Korea Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.5 India Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
8.3.7 Australia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Endogenous Peptide Substances Consumption Value by Type (2018-2029)
9.2 South America Endogenous Peptide Substances Consumption Value by Application (2018-2029)
9.3 South America Endogenous Peptide Substances Market Size by Country
9.3.1 South America Endogenous Peptide Substances Consumption Value by Country (2018-2029)
9.3.2 Brazil Endogenous Peptide Substances Market Size and Forecast (2018-2029)
9.3.3 Argentina Endogenous Peptide Substances Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Endogenous Peptide Substances Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Endogenous Peptide Substances Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Endogenous Peptide Substances Market Size by Country
10.3.1 Middle East & Africa Endogenous Peptide Substances Consumption Value by Country (2018-2029)
10.3.2 Turkey Endogenous Peptide Substances Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Endogenous Peptide Substances Market Size and Forecast (2018-2029)
10.3.4 UAE Endogenous Peptide Substances Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Endogenous Peptide Substances Market Drivers
11.2 Endogenous Peptide Substances Market Restraints
11.3 Endogenous Peptide Substances Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Endogenous Peptide Substances Industry Chain
12.2 Endogenous Peptide Substances Upstream Analysis
12.3 Endogenous Peptide Substances Midstream Analysis
12.4 Endogenous Peptide Substances Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Endogenous Peptide Substances Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Endogenous Peptide Substances Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Endogenous Peptide Substances Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Endogenous Peptide Substances Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Assertio Therapeutics Inc. Company Information, Head Office, and Major Competitors
Table 6. Assertio Therapeutics Inc. Major Business
Table 7. Assertio Therapeutics Inc. Endogenous Peptide Substances Product and Solutions
Table 8. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Assertio Therapeutics Inc. Recent Developments and Future Plans
Table 10. Cipher Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 11. Cipher Pharmaceuticals Inc. Major Business
Table 12. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product and Solutions
Table 13. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Cipher Pharmaceuticals Inc. Recent Developments and Future Plans
Table 15. Endo International Plc Company Information, Head Office, and Major Competitors
Table 16. Endo International Plc Major Business
Table 17. Endo International Plc Endogenous Peptide Substances Product and Solutions
Table 18. Endo International Plc Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Endo International Plc Recent Developments and Future Plans
Table 20. Biosynth Carbosynth Company Information, Head Office, and Major Competitors
Table 21. Biosynth Carbosynth Major Business
Table 22. Biosynth Carbosynth Endogenous Peptide Substances Product and Solutions
Table 23. Biosynth Carbosynth Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biosynth Carbosynth Recent Developments and Future Plans
Table 25. Lannett Co. Inc. Company Information, Head Office, and Major Competitors
Table 26. Lannett Co. Inc. Major Business
Table 27. Lannett Co. Inc. Endogenous Peptide Substances Product and Solutions
Table 28. Lannett Co. Inc. Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Lannett Co. Inc. Recent Developments and Future Plans
Table 30. Pfizer Company Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Endogenous Peptide Substances Product and Solutions
Table 33. Pfizer Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Pfizer Recent Developments and Future Plans
Table 35. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Endogenous Peptide Substances Product and Solutions
Table 38. Johnson & Johnson Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Johnson & Johnson Recent Developments and Future Plans
Table 40. Peptide Institute Company Information, Head Office, and Major Competitors
Table 41. Peptide Institute Major Business
Table 42. Peptide Institute Endogenous Peptide Substances Product and Solutions
Table 43. Peptide Institute Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Peptide Institute Recent Developments and Future Plans
Table 45. Abbexa Company Information, Head Office, and Major Competitors
Table 46. Abbexa Major Business
Table 47. Abbexa Endogenous Peptide Substances Product and Solutions
Table 48. Abbexa Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Abbexa Recent Developments and Future Plans
Table 50. Phoenix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Phoenix Pharmaceuticals Major Business
Table 52. Phoenix Pharmaceuticals Endogenous Peptide Substances Product and Solutions
Table 53. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Phoenix Pharmaceuticals Recent Developments and Future Plans
Table 55. Creative Peptides Company Information, Head Office, and Major Competitors
Table 56. Creative Peptides Major Business
Table 57. Creative Peptides Endogenous Peptide Substances Product and Solutions
Table 58. Creative Peptides Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Creative Peptides Recent Developments and Future Plans
Table 60. Global Endogenous Peptide Substances Revenue (USD Million) by Players (2018-2023)
Table 61. Global Endogenous Peptide Substances Revenue Share by Players (2018-2023)
Table 62. Breakdown of Endogenous Peptide Substances by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Endogenous Peptide Substances, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 64. Head Office of Key Endogenous Peptide Substances Players
Table 65. Endogenous Peptide Substances Market: Company Product Type Footprint
Table 66. Endogenous Peptide Substances Market: Company Product Application Footprint
Table 67. Endogenous Peptide Substances New Market Entrants and Barriers to Market Entry
Table 68. Endogenous Peptide Substances Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Endogenous Peptide Substances Consumption Value (USD Million) by Type (2018-2023)
Table 70. Global Endogenous Peptide Substances Consumption Value Share by Type (2018-2023)
Table 71. Global Endogenous Peptide Substances Consumption Value Forecast by Type (2024-2029)
Table 72. Global Endogenous Peptide Substances Consumption Value by Application (2018-2023)
Table 73. Global Endogenous Peptide Substances Consumption Value Forecast by Application (2024-2029)
Table 74. North America Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 75. North America Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 76. North America Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 77. North America Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 78. North America Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 79. North America Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 80. Europe Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Europe Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Europe Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 83. Europe Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 84. Europe Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 87. Asia-Pacific Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 88. Asia-Pacific Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 89. Asia-Pacific Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 90. Asia-Pacific Endogenous Peptide Substances Consumption Value by Region (2018-2023) & (USD Million)
Table 91. Asia-Pacific Endogenous Peptide Substances Consumption Value by Region (2024-2029) & (USD Million)
Table 92. South America Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 93. South America Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 94. South America Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 95. South America Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 96. South America Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 97. South America Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Middle East & Africa Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 99. Middle East & Africa Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 100. Middle East & Africa Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 101. Middle East & Africa Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 102. Middle East & Africa Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 103. Middle East & Africa Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 104. Endogenous Peptide Substances Raw Material
Table 105. Key Suppliers of Endogenous Peptide Substances Raw Materials
Table 1. Global Endogenous Peptide Substances Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Endogenous Peptide Substances Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Endogenous Peptide Substances Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Endogenous Peptide Substances Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Assertio Therapeutics Inc. Company Information, Head Office, and Major Competitors
Table 6. Assertio Therapeutics Inc. Major Business
Table 7. Assertio Therapeutics Inc. Endogenous Peptide Substances Product and Solutions
Table 8. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Assertio Therapeutics Inc. Recent Developments and Future Plans
Table 10. Cipher Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 11. Cipher Pharmaceuticals Inc. Major Business
Table 12. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product and Solutions
Table 13. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Cipher Pharmaceuticals Inc. Recent Developments and Future Plans
Table 15. Endo International Plc Company Information, Head Office, and Major Competitors
Table 16. Endo International Plc Major Business
Table 17. Endo International Plc Endogenous Peptide Substances Product and Solutions
Table 18. Endo International Plc Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Endo International Plc Recent Developments and Future Plans
Table 20. Biosynth Carbosynth Company Information, Head Office, and Major Competitors
Table 21. Biosynth Carbosynth Major Business
Table 22. Biosynth Carbosynth Endogenous Peptide Substances Product and Solutions
Table 23. Biosynth Carbosynth Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biosynth Carbosynth Recent Developments and Future Plans
Table 25. Lannett Co. Inc. Company Information, Head Office, and Major Competitors
Table 26. Lannett Co. Inc. Major Business
Table 27. Lannett Co. Inc. Endogenous Peptide Substances Product and Solutions
Table 28. Lannett Co. Inc. Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Lannett Co. Inc. Recent Developments and Future Plans
Table 30. Pfizer Company Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Endogenous Peptide Substances Product and Solutions
Table 33. Pfizer Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Pfizer Recent Developments and Future Plans
Table 35. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Endogenous Peptide Substances Product and Solutions
Table 38. Johnson & Johnson Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Johnson & Johnson Recent Developments and Future Plans
Table 40. Peptide Institute Company Information, Head Office, and Major Competitors
Table 41. Peptide Institute Major Business
Table 42. Peptide Institute Endogenous Peptide Substances Product and Solutions
Table 43. Peptide Institute Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Peptide Institute Recent Developments and Future Plans
Table 45. Abbexa Company Information, Head Office, and Major Competitors
Table 46. Abbexa Major Business
Table 47. Abbexa Endogenous Peptide Substances Product and Solutions
Table 48. Abbexa Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Abbexa Recent Developments and Future Plans
Table 50. Phoenix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Phoenix Pharmaceuticals Major Business
Table 52. Phoenix Pharmaceuticals Endogenous Peptide Substances Product and Solutions
Table 53. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Phoenix Pharmaceuticals Recent Developments and Future Plans
Table 55. Creative Peptides Company Information, Head Office, and Major Competitors
Table 56. Creative Peptides Major Business
Table 57. Creative Peptides Endogenous Peptide Substances Product and Solutions
Table 58. Creative Peptides Endogenous Peptide Substances Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Creative Peptides Recent Developments and Future Plans
Table 60. Global Endogenous Peptide Substances Revenue (USD Million) by Players (2018-2023)
Table 61. Global Endogenous Peptide Substances Revenue Share by Players (2018-2023)
Table 62. Breakdown of Endogenous Peptide Substances by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Endogenous Peptide Substances, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 64. Head Office of Key Endogenous Peptide Substances Players
Table 65. Endogenous Peptide Substances Market: Company Product Type Footprint
Table 66. Endogenous Peptide Substances Market: Company Product Application Footprint
Table 67. Endogenous Peptide Substances New Market Entrants and Barriers to Market Entry
Table 68. Endogenous Peptide Substances Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Endogenous Peptide Substances Consumption Value (USD Million) by Type (2018-2023)
Table 70. Global Endogenous Peptide Substances Consumption Value Share by Type (2018-2023)
Table 71. Global Endogenous Peptide Substances Consumption Value Forecast by Type (2024-2029)
Table 72. Global Endogenous Peptide Substances Consumption Value by Application (2018-2023)
Table 73. Global Endogenous Peptide Substances Consumption Value Forecast by Application (2024-2029)
Table 74. North America Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 75. North America Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 76. North America Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 77. North America Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 78. North America Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 79. North America Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 80. Europe Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Europe Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Europe Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 83. Europe Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 84. Europe Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 87. Asia-Pacific Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 88. Asia-Pacific Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 89. Asia-Pacific Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 90. Asia-Pacific Endogenous Peptide Substances Consumption Value by Region (2018-2023) & (USD Million)
Table 91. Asia-Pacific Endogenous Peptide Substances Consumption Value by Region (2024-2029) & (USD Million)
Table 92. South America Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 93. South America Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 94. South America Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 95. South America Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 96. South America Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 97. South America Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Middle East & Africa Endogenous Peptide Substances Consumption Value by Type (2018-2023) & (USD Million)
Table 99. Middle East & Africa Endogenous Peptide Substances Consumption Value by Type (2024-2029) & (USD Million)
Table 100. Middle East & Africa Endogenous Peptide Substances Consumption Value by Application (2018-2023) & (USD Million)
Table 101. Middle East & Africa Endogenous Peptide Substances Consumption Value by Application (2024-2029) & (USD Million)
Table 102. Middle East & Africa Endogenous Peptide Substances Consumption Value by Country (2018-2023) & (USD Million)
Table 103. Middle East & Africa Endogenous Peptide Substances Consumption Value by Country (2024-2029) & (USD Million)
Table 104. Endogenous Peptide Substances Raw Material
Table 105. Key Suppliers of Endogenous Peptide Substances Raw Materials
LIST OF FIGURES
Figure 1. Endogenous Peptide Substances Picture
Figure 2. Global Endogenous Peptide Substances Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Endogenous Peptide Substances Consumption Value Market Share by Type in 2022
Figure 4. Neuropeptides
Figure 5. Hormones
Figure 6. Cytokines
Figure 7. Peptide Hormones
Figure 8. Bioactive Peptides
Figure 9. Global Endogenous Peptide Substances Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Endogenous Peptide Substances Consumption Value Market Share by Application in 2022
Figure 11. Research Picture
Figure 12. Medicine Picture
Figure 13. Others Picture
Figure 14. Global Endogenous Peptide Substances Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Endogenous Peptide Substances Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Endogenous Peptide Substances Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Endogenous Peptide Substances Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Endogenous Peptide Substances Consumption Value Market Share by Region in 2022
Figure 19. North America Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Endogenous Peptide Substances Revenue Share by Players in 2022
Figure 25. Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Endogenous Peptide Substances Market Share in 2022
Figure 27. Global Top 6 Players Endogenous Peptide Substances Market Share in 2022
Figure 28. Global Endogenous Peptide Substances Consumption Value Share by Type (2018-2023)
Figure 29. Global Endogenous Peptide Substances Market Share Forecast by Type (2024-2029)
Figure 30. Global Endogenous Peptide Substances Consumption Value Share by Application (2018-2023)
Figure 31. Global Endogenous Peptide Substances Market Share Forecast by Application (2024-2029)
Figure 32. North America Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 42. France Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Endogenous Peptide Substances Consumption Value Market Share by Region (2018-2029)
Figure 49. China Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 52. India Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 66. Endogenous Peptide Substances Market Drivers
Figure 67. Endogenous Peptide Substances Market Restraints
Figure 68. Endogenous Peptide Substances Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Endogenous Peptide Substances in 2022
Figure 71. Manufacturing Process Analysis of Endogenous Peptide Substances
Figure 72. Endogenous Peptide Substances Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Endogenous Peptide Substances Picture
Figure 2. Global Endogenous Peptide Substances Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Endogenous Peptide Substances Consumption Value Market Share by Type in 2022
Figure 4. Neuropeptides
Figure 5. Hormones
Figure 6. Cytokines
Figure 7. Peptide Hormones
Figure 8. Bioactive Peptides
Figure 9. Global Endogenous Peptide Substances Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Endogenous Peptide Substances Consumption Value Market Share by Application in 2022
Figure 11. Research Picture
Figure 12. Medicine Picture
Figure 13. Others Picture
Figure 14. Global Endogenous Peptide Substances Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Endogenous Peptide Substances Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Endogenous Peptide Substances Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Endogenous Peptide Substances Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Endogenous Peptide Substances Consumption Value Market Share by Region in 2022
Figure 19. North America Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Endogenous Peptide Substances Revenue Share by Players in 2022
Figure 25. Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Endogenous Peptide Substances Market Share in 2022
Figure 27. Global Top 6 Players Endogenous Peptide Substances Market Share in 2022
Figure 28. Global Endogenous Peptide Substances Consumption Value Share by Type (2018-2023)
Figure 29. Global Endogenous Peptide Substances Market Share Forecast by Type (2024-2029)
Figure 30. Global Endogenous Peptide Substances Consumption Value Share by Application (2018-2023)
Figure 31. Global Endogenous Peptide Substances Market Share Forecast by Application (2024-2029)
Figure 32. North America Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 42. France Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Endogenous Peptide Substances Consumption Value Market Share by Region (2018-2029)
Figure 49. China Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 52. India Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Endogenous Peptide Substances Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Endogenous Peptide Substances Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Endogenous Peptide Substances Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)
Figure 66. Endogenous Peptide Substances Market Drivers
Figure 67. Endogenous Peptide Substances Market Restraints
Figure 68. Endogenous Peptide Substances Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Endogenous Peptide Substances in 2022
Figure 71. Manufacturing Process Analysis of Endogenous Peptide Substances
Figure 72. Endogenous Peptide Substances Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
